Clinical Trials: Country-Specific Clinical Trials

Clinical Trial Timelines in China vs Global Benchmarks

Posted on digi By digi

Sponsors can reduce delays by:
✔️ Engaging the NMPA early through pre-IND consultations
✔️ Preparing ethics submissions in parallel with IND filings
✔️ Partnering with CROs to support Tier-2 hospital activation
✔️ Establishing SOPs for recruitment and monitoring
✔️ Leveraging accelerated pathways for oncology, vaccine, and rare disease trials
These practices help align Chinese timelines with global benchmarks.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Medical Device Clinical Trials in India: Regulatory Framework and CDSCO Pathways

Posted on digi By digi

India’s medical device regulatory landscape is maturing, with defined provisions for clinical trials, ethics oversight, and post-market vigilance. Sponsors must navigate a separate pathway under the MDR 2017, distinct from drug trials governed by NDCTR. With increasing demand for device innovation and localization, India offers opportunities for early-phase device research backed by regulatory clarity, structured processes, and global harmonization. Proactive engagement with CDSCO and adherence to ISO 14155 can ensure compliance and trial success.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

MHRA Guidance on First-in-Human Studies in the UK

Posted on digi By digi

First-in-human trials in the UK are tightly regulated, requiring robust protocols, MHRA authorisation, and REC approval. Accredited Phase 1 units, combined with strong pharmacovigilance practices, ensure participant safety while enabling early clinical development. Sponsors must adopt comprehensive risk mitigation, maintain GCP compliance, and engage proactively with regulators. With MHRA’s rigorous oversight and NHS-supported infrastructure, the UK continues to be a leading destination for FIH studies, contributing to global drug development pipelines.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Role of Academia in European Clinical Trials

Posted on digi By digi

Academic trial responsibilities differ depending on therapeutic area and design:

Oncology: IITs often test novel combinations or repurposed drugs outside of commercial pipelines.
Rare Diseases: Small patient populations make academia essential for advancing therapeutic options.
Pediatrics: Ethics committees demand tailored informed consent and assent processes for minors.
Decentralized Trials: Academia often leads innovation in remote monitoring and patient-centric designs, requiring careful regulatory planning.

Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials

Adaptive Trial Designs in Indian Clinical Programs: Regulatory Perspectives and Emerging Practices

Posted on digi By digi

Adaptive trial designs offer Indian sponsors and global collaborators a powerful tool for efficient, ethical, and informative clinical research. While CDSCO does not yet offer formal guidance, there is growing recognition of adaptive methods, particularly in complex and urgent therapeutic areas. Early engagement with regulators, rigorous design planning, and transparent communication with stakeholders are essential to successfully implementing adaptive designs in the Indian clinical trial landscape.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

How CFDA Transition to NMPA Changed Clinical Trials

Posted on digi By digi

Sponsors should integrate China into global clinical development plans earlier, leveraging NMPA’s acceptance of multinational data. Early engagement with regulators through pre-IND consultations helps clarify expectations. CRO partnerships are critical for ensuring site readiness, ethics compliance, and inspection preparedness. Establishing harmonized SOPs across global and Chinese sites prevents compliance gaps.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Role of UK Research Ethics Committees (RECs) in Clinical Trials

Posted on digi By digi

Research Ethics Committees are a cornerstone of UK clinical trial governance, ensuring ethical conduct, participant protection, and scientific credibility. Working under HRA oversight and aligned with MHRA regulatory frameworks, RECs review trial protocols, consent procedures, and safety monitoring to ensure compliance with both ethical and scientific standards. Sponsors and investigators engaging with RECs should prioritise transparency, participant-focused communication, and robust safety planning to maintain public trust and regulatory acceptance of UK trial data.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

EU Requirements for Non-EU Sponsors in Clinical Trials

Posted on digi By digi

Obligations differ depending on trial type:

Oncology Trials: Require complex pharmacovigilance systems due to high SAE incidence.
Pediatrics: Additional requirements include Pediatric Investigation Plans (PIPs) and tailored consent processes.
Rare Diseases: Cross-border collaboration often necessitates multi-country CTIS submissions with harmonized oversight.
Advanced Therapies: Long-term monitoring obligations extend beyond trial completion.

Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials

Role of NABH Accreditation in Clinical Trial Site Selection in India

Posted on digi By digi

Incorporating NABH accreditation as a clinical trial site selection criterion in India provides measurable benefits in quality, compliance, and operational excellence. While not a regulatory requirement, NABH-accredited institutions align with global GCP standards, enhance audit readiness, and contribute to reliable trial conduct. As India’s clinical trial landscape expands, leveraging NABH as a quality marker will support more consistent and inspection-resilient trial execution.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Clinical Pharmacology Studies in China: A Regulatory Perspective

Posted on digi By digi

Sponsors should plan pharmacology studies with early engagement of NMPA and ethics committees. Selecting accredited Phase I units, ensuring robust CRO partnerships, and validating EDC systems are essential. Patient and volunteer safety should remain central, with clear SOPs for adverse event management and informed consent.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials